idea-007 · vet · US
For placement by a licensed veterinarian to provide repeated subcutaneous administration of isotonic crystalloid fluids by the owner at home, in cats with chronic kidney disease requiring ongoing fluid therapy, as an alternative to repeated percutaneous needle sticks.
Finished enough to read, and waiting for you. No department has been asked. 2 of 48 claims verified. Nobody has yet written down what it rests on.
An implanted port that lets an owner give a cat with kidney disease its fluids without a needle each time. Cats with chronic kidney disease need fluid under the skin several times a week, usually for the rest of their lives, and most owners do it at home with a needle and a bag. It is unpleasant for the cat and many owners skip sessions. This device is a small port placed under the skin in a short operation, with a soft perforated tube that spreads the fluid; the owner connects a pre-measured giving set to the port instead of inserting a needle. Its two design bets are a surface chemistry meant to keep the body from reacting to the implant over years, and a metered giving set that makes each session a fixed dose. There is no FDA (US Food and Drug Administration) premarket review for animal devices and no insurance — the owner pays.
In the Wrap's one-paragraph version, written for someone who has not opened the file. Domain: feline-ckd-subcutaneous-fluid-therapy
The budget-holder chain has one cheque in it, and it is written entirely out of discretionary household spending — there is no second cheque from a payer sitting behind it, and that is a structural fact about this candidate rather than a gap in this repo's connectors.
hcpcs, payment and coverage were deliberately not run
against this candidate, for the same reason the candidate file itself gives: those
connectors query CMS (Centers for Medicare & Medicaid Services), which has no jurisdiction over veterinary care, and a null from any
of them would be a category error dressed as a finding, not evidence about this market.
Pet insurance offsets part of the bill for a minority of owners, at a rate no claim in this
file quantifies claim 7unconfirmed, sharpened here as [assumption A3].
adoption returned unverifiable (quoted below). This
candidate does not enter an empty comparator field; it enters one with an incumbent
practice and at least one incumbent product.
The chain's weakest link is that there is only one link, and its size is unmeasured. Unlike a human-medicine device with a payer setting a ceiling, this candidate's entire revenue model rests on what one owner will pay one time plus what they will pay monthly after — and no claim in this file, and no connector this repo can reach, prices either number.
What this idea rests on that is not yet known, in the order this idea's own decision queue puts it: worst if false first, cheapest to settle first inside that. The first row is open; open any other for what would settle it.
This idea is unassessed, so nobody has yet named the few things it rests on. Until then, the gaps below are the rubric factors that are unscored or carry an open question. /assess idea-007 replaces this list with the real one.
Why it scored what it did: intended_use: is present (vet-only, feline, subcutaneous crystalloid hydration, owner-administered), so Factor 1 is scorable. Rests on claims 1 (animal-only devices not subject to 510(k) (premarket notification)/PMA) and 2 (no establishment registration /…the rest of this reasoning
device listing for exclusively-veterinary devices). device_class: n/a is read as the template intends — no referent, not unknown — so this is a score on review burden, and the burden is approximately zero: no submission, no user fee, no predicate, no premarket clinical evidence. Note this is not free upside: the same absence of review is what drives Factor 5 down via claim 12unconfirmed, and it is the boundary in the second device_class entry that keeps it — any human-use claim on this hardware relocates it to Class II (FDA device class II)/510(k) with a crowded predicate field and a live patent estate.
What would settle it: claim 1unconfirmed needs the FDA Compliance Policy Guide (Sec. 300.100/7124.29) or a regulatory-counsel opinion, human-attached — free document, but requires legal reading; no connector reaches CPG guidance text.
Why it scored what it did: Rests on claim 7unconfirmed. Scored, not left open: "there is no third-party payer code of any kind for veterinary hydration therapy" is a structural fact about the business model, not a pending lookup. 1 rather than 0 because a functioning…the rest of this reasoning
revenue mechanism does exist — cash-pay at point of service, with partial offset for the minority of owners carrying pet insurance — and it carries no coverage-determination risk and no fee-schedule ceiling. 1 rather than higher because the rubric's Factor 2 is written over codes and payer coverage precedent, and here there are none and there will never be any. Kill-condition note for Stage 5: floor is breached only if Regulatory is also below 2, and it is not.
What would settle it: No connector applies — CMS has no veterinary jurisdiction. A licensed NAPHIA pet-insurance report (paid) and a veterinary distributor cash-pricing catalogue (free) are the only human-attachable sources.
Why it scored what it did: Rests on claims 8, 9 and 10 — and all three are Generator assumptions with no number attached to component 1 at all. 2 is a triage placeholder built on: feline CKD (chronic kidney disease) being a high-prevalence condition of older cats (widely believed,…the rest of this reasoning
unsourced here), the assumed $250-450 implant kit plus $180-360/yr consumables (claim 9unconfirmed), and the assumed 10-20% obtainable share (claim 10unconfirmed). The obtainable segment is defined by owner attrition from needle-stick therapy, which claim 10unconfirmed concedes no source here measures. Held at 2 rather than 3 because the population denominator is genuinely absent, not merely uncertain — this sits exactly on the 2/5 kill floor and one bad denominator moves it under.
What would settle it: Component 1: VetCompass US or Banfield/Mars State of Pet Health prevalence tables — human-attached, free/licensed. Component 2: a current veterinary distributor catalogue (Covetrus, Patterson Vet, MWI) — free, cheapest input to fix.…the rest of this gap analysis
Component 3: only a practice survey or pilot on owner attrition would test it — Tier 3, cost varies.
Why it scored what it did: Deliberately unscored: no claim in this file addresses blocking patents, FTO (freedom to operate), or expiration timelines. claim 11unconfirmed is a moat claim (what could be patented by us) and is scored under Factor 5; it is not FTO evidence and must not be…the rest of this reasoning
borrowed as such. The nearest thing in the file is the second device_class entry's mention of a live patent estate around human-use implanted ports, which is frontmatter framing, not a claim, and points the wrong way besides. Not guessed and not zeroed — a blank here is "we have not looked," and Factor 4 carries an automatic kill condition, so it is the single most valuable row to resolve.
What would settle it: A PatentsView prior-art search (needs a free PATENTSVIEW_API_KEY) on implanted subcutaneous ports, low-fouling implant coatings, and metered giving sets, plus the SUB device manufacturer's own US patents.
Why it scored what it did: Rests on claims 11 and 12. claim 11unconfirmed names two plausibly defensible assets — low-fouling implant surface chemistry and a metered giving set that makes owner dosing error hard — and concedes the silicone port body is a commodity conferring…the rest of this reasoning
nothing. claim 12unconfirmed is the offset and it is a strong one: with no premarket review, a fast-follower faces only tooling, sterile packaging validation and distribution, so there is no regulatory delay acting as a moat the way it would for a Class II human device. claim 3unconfirmed compounds this — the category already exists in feline practice, so this is entry into an occupied space, not creation of one. Held at 2: real levers, none of them yet reduced to practice or filed. Note claim 12unconfirmed is explicitly a deduction from claims 1 and 2, both unverified — if those fall, this row moves.
What would settle it: Same PatentsView search as Factor 4 covers patentability of the two named levers (free, needs API key). The rest — switching costs, training lock-in, distributor relationships — settles only through a filed provisional reviewed by patent…the rest of this gap analysis
counsel, Tier 3 and not cheap.
Why it scored what it did: Rests on claims 4, 5 and 13, with 3 and 6 as feasibility support. The split matters: mechanical plausibility is high — subcutaneous fluid ports are already in feline clinical use (claim 3unconfirmed) and the SUB device is an existence proof that…the rest of this reasoning
owners and surgeons accept a lifelong implanted feline port (claim 6unconfirmed). The score is dragged down by oncologic risk (claim 13unconfirmed), which the file itself calls the line the product stands or falls on. claim 5unconfirmed (feline injection-site sarcoma as an inflammation-associated entity) is flagged by the Generator as general knowledge with no source read, and claim 4unconfirmed is a single case report of sarcoma at a subcutaneous fluid port — bibliographic existence only, no denominator, no incidence, no causal finding. The premise that better material, geometry and a resectable non-interscapular site reduce that risk is unasserted by design (claim 13unconfirmed) and is precisely what an animal study would have to demonstrate. 2, not lower, because the failure mode is at least correctly identified and designed against.
What would settle it: A full read of PMC11383148, the feline injection-site-sarcoma literature, and the SUB complication PMC records already surfaced by title would sharpen this — free, a few hours of Tier 3 reading. Only a prospective multi-year feline case…the rest of this gap analysis
series can actually quantify the oncologic risk — Tier 3, expensive.
Why it scored what it did: Rests on claim 14unconfirmed, with claim 1unconfirmed as the enabling condition. Low-single-digit millions to first revenue is credible given no premarket submission, no user fee and no FDA clinical evidence requirement (claim 1unconfirmed) — cost is dominated by implant…the rest of this reasoning
material qualification, sterile packaging validation and tooling. The reason this is 3 and not 4 is calendar, not cash: claim 14unconfirmed correctly identifies that the pacing item is a prospective teaching-hospital case series with follow-up long enough to say anything about tumour incidence, and oncologic follow-up in a species where the risk window is years is not compressible with money. There is also a real tension the Generator does not resolve — nothing legally requires that study before sale, so "time to first revenue" and "time to defensible revenue" are different numbers here and only the second is scored.
What would settle it: Cost side: contract-manufacturer quotes for ISO (International Organization for Standardization) 10993 biocompatibility and ISO 11607 sterile-barrier testing plus tooling — cheap, a few RFQs. Calendar side: a partner teaching-hospital's study protocol and IACUC timeline — Tier 3, no cost…the rest of this gap analysis
estimate without one.
Why it scored what it did: Rests on claims 15 and 3. Incumbents are named and real: existing feline subcutaneous fluid port products already marketed as a needleless alternative to daily injections (claim 3unconfirmed), and the SUB device manufacturer in the adjacent…the rest of this reasoning
indication (claims 6, 15). claim 3unconfirmed explicitly notes the category's existence cuts against novelty as much as it supports feasibility. Combined with claim 12unconfirmed's zero regulatory barrier to a fast-follower, the space should be read as occupied and cheap to enter. 2 rather than lower because the named incumbents are small and the specific combination claimed here (low-fouling surface + metered owner-operated giving set + non-interscapular sited implant) does not obviously exist in a marketed product.
What would settle it: Veterinary trade sources, human-attached: distributor catalogues (Covetrus, Patterson Vet, MWI), VMX/WVC exhibitor lists, ACVIM/ACVS abstract books — free to pull, time-cost to compile. PatentsView (free once keyed) is the one database…the rest of this gap analysis
that does see this field.
Why it scored what it did: Unscored for two independent reasons. First, no claim in this file addresses portfolio fit — nothing to rest a score on, and Stage 2 does not invent one. Second, and more fundamental, there is no portfolio-state document anywhere in…the rest of this reasoning
this repo to score against: knowledge-base/candidates/ holds eight unrelated in-flight ideas, none of which constitutes a stated portfolio thesis, capital position, or hero-bet/cash-spoke allocation. Scoring "fit" with no referent would be a number about nothing. Worth recording for the humans that this candidate's shape is legible even unscored — vet-only, cash-pay, low regulatory burden, modest TAM (total addressable market) — which reads as a cash-generative spoke rather than a hero bet, but whether that is wanted is not an agent's call.
What would settle it: A human-stated portfolio thesis and capital-allocation posture at Stage 6 shortlist review — no cost beyond that conversation; no connector or literature can supply it.
Seven chairs, each answering from its own field. The verdict, and the first condition it set.
Not convened. No department has stated a position on this idea yet — a normal state, not a defect. /round-table idea-007 asks all seven.
Only verified counts toward a score. A low count is usually a statement about the tooling — an absent data file, an unset key — rather than about the idea.
No claim on this idea has been refuted.
Read PMID (PubMed identifier) 40011049 — the SUB long-term outcomes study — closely enough to establish whether the chronic device mineralization it reports in 19-50% of implants is a urine-chemistry phenomenon that would not transfer to a port carrying crystalloid, or a surface-and-dwell-time phenomenon that would. The file's gap analysis names the SUB precedent as the nearest available proxy for how an implanted feline port behaves over years; this is the specific question that proxy now raises. One hour of reading, standing in front of a multi-year study, and it changes the material-qualification programme, the case-series design and the moat argument at once. Selected from the Mechanism and Moat rows' gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Only verified counts toward a score. A low count is usually a statement about the tooling (an absent data file, an unset key) rather than about the idea.
Evaluated 2026-08-23 against the Verified Composite above, using verified claims only. The Stage 2 draft table was not consulted. Unchecked boxes below mean the condition did not fire — in this file, in every case, because the data the condition reads does not exist yet. A condition that cannot be evaluated is not a condition that passed.
unconfirmed — the Scorer scored it on structural grounds (veterinary care has no
code-issuing payer) while deliberately excluding it from the verified counts. **This gate
therefore does not read that 1 as verified data**, which is exactly why the Scorer wrote it
as a scored-but-uncounted row rather than leaving an undefined operand for Stage 5 to fill
with a zero. On verified data this condition has one operand at the floor and one absent.
unconfirmed. The population denominator is human-attached only — no connector in this repo
reaches veterinary epidemiology.
PATENTSVIEW_API_KEY is unset. Worth flagging against this candidate specifically: FDA's
absence from animal-only devices does not extend to patents. A live US patent is
enforceable against a vet-labelled device exactly as against a human-use one, so this is the
one core factor where the veterinary framing buys no relief at all.
Every one of the three kill conditions is written over a core factor — Regulatory, Reimbursement, TAM, FTO. Of those four, exactly one (Regulatory, 2/5) has a verified claim behind it, and it sits at its floor rather than below it. Reimbursement is scored but uncounted, TAM is blank, FTO is unexamined. So the gate is not reporting that this candidate survived scrutiny; it is reporting that the scrutiny the gate performs has nothing to read. Recording that distinction is the whole point of separating queued-research from gated-out: "we don't know yet" is not "the answer is no."
data/ cache is a red herring for this file — a fully populated cache would change nothing here.
status: set to queued-research; stage: stays verified — the
Verifier attempted every claim, so the pass is complete and must not be regressed.
wrapped is not an approval — it means a human can now read this.
No human review is recorded. Shortlisting, legal and clinical sign-off and capital allocation are Tier 3: no agent in this repo makes or simulates one. The packet is wrapped, so it can be read now.
Runs only after a human shortlists the idea.
No loop record: nobody has written down what this idea rests on or convened a department on it. That is a normal state, not a defect. /front-end-loop idea-007 opens one.
Nobody has yet written down what this idea rests on and what it would cost to be wrong. Unassessed is a state, not a low score. /assess idea-007 adds it.
Click any step to see what it holds for this idea. donecurrentloopinghuman only
## Wrap section, as writtenThe packet a human reads. See docs/wrap-spec.md. This section says nothing about whether the idea is good — it says the file is finished enough to be read, and names what to do next. Filling it in advances no candidate and approves nothing.
The one-paragraph version. An implanted port that lets an owner give a cat with kidney disease its fluids without a needle each time. Cats with chronic kidney disease need fluid under the skin several times a week, usually for the rest of their lives, and most owners do it at home with a needle and a bag. It is unpleasant for the cat and many owners skip sessions. This device is a small port placed under the skin in a short operation, with a soft perforated tube that spreads the fluid; the owner connects a pre-measured giving set to the port instead of inserting a needle. Its two design bets are a surface chemistry meant to keep the body from reacting to the implant over years, and a metered giving set that makes each session a fixed dose. There is no FDA premarket review for animal devices and no insurance — the owner pays.
What would have to be true, quoted from each deck's load-bearing condition:
Cheapest next test: Read PMID 40011049 — the SUB long-term outcomes study — closely enough to establish whether the chronic device mineralization it reports in 19-50% of implants is a urine-chemistry phenomenon that would not transfer to a port carrying crystalloid, or a surface-and-dwell-time phenomenon that would. The file's gap analysis names the SUB precedent as the nearest available proxy for how an implanted feline port behaves over years; this is the specific question that proxy now raises. One hour of reading, standing in front of a multi-year study, and it changes the material-qualification programme, the case-series design and the moat argument at once. Selected from the Mechanism and Moat rows' gap analysis; this is a selection from it, not a new judgement, and not a view about the idea.
Where the evidence actually stands. 2 of 39 claims verified, 37 unconfirmed, none refuted — the thinnest verified position in the wrapped set alongside idea-004. All 9 factors carry a score in the Stage 2 triage table and all 4 core factors do.
Both verified claims are regulatory classification: veterinary-only manufacturers need not register or list devices with FDA claim 2verified, and human implanted vascular access ports are Class II under 21 CFR (Title 21 of the Code of Federal Regulations) 880.5965, product code PXK claim 36verified. No commercial claim in this file has ever been verified, and on current tooling none can be — the connectors that produce real numbers elsewhere in this pipeline are CMS and openFDA, and neither sees a veterinary market. An empty FDA scan here is coverage absence, never competitive absence.
Eleven claims were added by the research lane since 2026-08-24 and not one moved a tag. They nevertheless spent this candidate's previously-named cheapest next test, and the results matter in three directions.
Demand is now the best-evidenced part of the file. In a survey of 468 owners of CKD cats, 399 (85%) were giving subcutaneous fluids at home claim 29unconfirmed, and among those, 155 of 399 (39%) reported skipping doses in the prior 2-4 weeks because their cat was frustrated claim 30unconfirmed. The premise this product is built on — that the needle regimen lapses — is measured rather than assumed.
The nearest device precedent was read, and it is two-sided. The previous decks said three times that the subcutaneous ureteral bypass literature had been "located by title, never read". It has been. In 95 SUB devices across 66 cats, chronic device mineralization occurred in 19-50% of devices and chronic urinary tract infection in 3-33% of cats, varying with flush protocol claim 32unconfirmed. Against that, comparing device generations in 80 cats, catheter kinking fell from 15.5% to 0% and 90-day survival rose from 75% to 94% claim 33unconfirmed — implanted feline ports have characterisable, improvable failure modes, and the incumbent is actively improving them. Human implanted ports are reassuring by comparison — 0.05 catheter-related bloodstream infections per 1,000 catheter-days claim 34unconfirmed, early infection in 1.2% of 1,714 placements claim 35unconfirmed — but those are clinician-accessed ports, not ports accessed by an untrained owner at a kitchen table several times a week.
A second clock appeared that the capital plan does not carry. The file prices a case series as a line item against an oncologic endpoint that needs years. The SUB record says a device-durability problem would land first and could end the programme on its own. Costing one series against one endpoint understates both the money and the calendar.
Two cautions on reading the rest. The two prevalence figures the research lane returned are not reconcilable at face value — 50% in a US feline-only practice cohort claim 38unconfirmed against 1.2% in a UK primary-care cohort of 353,448 cats claim 39unconfirmed — because they are answering different questions, and a TAM built on either without saying which is a number without a meaning. And FTO is unexamined rather than clear claim 28unconfirmed: never asked, on the rubric's one automatic-kill factor, against an incumbent that is demonstrably an active device developer in this exact species and anatomy. On a candidate whose only other barrier to entry is tooling, the patent position is the whole defence.
| Factor | Score | Why | What would settle it |
|---|---|---|---|
| Regulatory pathway | 5 | intended_use: is present (vet-only, feline, subcutaneous crystalloid hydration, owner-administered), so Factor 1 is scorable. Rests on claims 1 (animal-only devices not subject to 510(k)/PMA) and 2 (no establishment registration /…the rest of this reasoningdevice listing for exclusively-veterinary devices).device_class: n/a is read as the template intends — no referent, not unknown — so this is a score on review burden, and the burden is approximately zero: no submission, no user fee, no predicate, no premarket clinical evidence. Note this is not free upside: the same absence of review is what drives Factor 5 down via claim 12unconfirmed, and it is the boundary in the second device_class entry that keeps it — any human-use claim on this hardware relocates it to Class II/510(k) with a crowded predicate field and a live patent estate. | claim 1unconfirmed needs the FDA Compliance Policy Guide (Sec. 300.100/7124.29) or a regulatory-counsel opinion, human-attached — free document, but requires legal reading; no connector reaches CPG guidance text. |
| Reimbursement pathway | 1 | Rests on claim 7unconfirmed. Scored, not left open: "there is no third-party payer code of any kind for veterinary hydration therapy" is a structural fact about the business model, not a pending lookup. 1 rather than 0 because a functioning…the rest of this reasoningrevenue mechanism does exist — cash-pay at point of service, with partial offset for the minority of owners carrying pet insurance — and it carries no coverage-determination risk and no fee-schedule ceiling. 1 rather than higher because the rubric's Factor 2 is written over codes and payer coverage precedent, and here there are none and there will never be any. Kill-condition note for Stage 5: floor is breached only if Regulatory is also below 2, and it is not. | No connector applies — CMS has no veterinary jurisdiction. A licensed NAPHIA pet-insurance report (paid) and a veterinary distributor cash-pricing catalogue (free) are the only human-attachable sources. |
| TAM | 2 | Rests on claims 8, 9 and 10 — and all three are Generator assumptions with no number attached to component 1 at all. 2 is a triage placeholder built on: feline CKD being a high-prevalence condition of older cats (widely believed,…the rest of this reasoningunsourced here), the assumed $250-450 implant kit plus $180-360/yr consumables (claim 9unconfirmed), and the assumed 10-20% obtainable share (claim 10unconfirmed). The obtainable segment is defined by owner attrition from needle-stick therapy, which claim 10unconfirmed concedes no source here measures. Held at 2 rather than 3 because the population denominator is genuinely absent, not merely uncertain — this sits exactly on the 2/5 kill floor and one bad denominator moves it under. | Component 1: VetCompass US or Banfield/Mars State of Pet Health prevalence tables — human-attached, free/licensed. Component 2: a current veterinary distributor catalogue (Covetrus, Patterson Vet, MWI) — free, cheapest input to fix.…the rest of this gap analysisComponent 3: only a practice survey or pilot on owner attrition would test it — Tier 3, cost varies. |
| FTO / IP | *(blank — no claim)* | Deliberately unscored: no claim in this file addresses blocking patents, FTO, or expiration timelines. claim 11unconfirmed is a moat claim (what could be patented by us) and is scored under Factor 5; it is not FTO evidence and must not be…the rest of this reasoningborrowed as such. The nearest thing in the file is the seconddevice_class entry's mention of a live patent estate around human-use implanted ports, which is frontmatter framing, not a claim, and points the wrong way besides. Not guessed and not zeroed — a blank here is "we have not looked," and Factor 4 carries an automatic kill condition, so it is the single most valuable row to resolve. | A PatentsView prior-art search (needs a free PATENTSVIEW_API_KEY) on implanted subcutaneous ports, low-fouling implant coatings, and metered giving sets, plus the SUB device manufacturer's own US patents. |
| Moat / defensibility | 2 | Rests on claims 11 and 12. claim 11unconfirmed names two plausibly defensible assets — low-fouling implant surface chemistry and a metered giving set that makes owner dosing error hard — and concedes the silicone port body is a commodity conferring…the rest of this reasoningnothing. claim 12unconfirmed is the offset and it is a strong one: with no premarket review, a fast-follower faces only tooling, sterile packaging validation and distribution, so there is no regulatory delay acting as a moat the way it would for a Class II human device. claim 3unconfirmed compounds this — the category already exists in feline practice, so this is entry into an occupied space, not creation of one. Held at 2: real levers, none of them yet reduced to practice or filed. Note claim 12unconfirmed is explicitly a deduction from claims 1 and 2, both unverified — if those fall, this row moves. | Same PatentsView search as Factor 4 covers patentability of the two named levers (free, needs API key). The rest — switching costs, training lock-in, distributor relationships — settles only through a filed provisional reviewed by patent…the rest of this gap analysiscounsel, Tier 3 and not cheap. |
| Mechanism & clinical risk | 2 | Rests on claims 4, 5 and 13, with 3 and 6 as feasibility support. The split matters: mechanical plausibility is high — subcutaneous fluid ports are already in feline clinical use (claim 3unconfirmed) and the SUB device is an existence proof that…the rest of this reasoningowners and surgeons accept a lifelong implanted feline port (claim 6unconfirmed). The score is dragged down by oncologic risk (claim 13unconfirmed), which the file itself calls the line the product stands or falls on. claim 5unconfirmed (feline injection-site sarcoma as an inflammation-associated entity) is flagged by the Generator as general knowledge with no source read, and claim 4unconfirmed is a single case report of sarcoma at a subcutaneous fluid port — bibliographic existence only, no denominator, no incidence, no causal finding. The premise that better material, geometry and a resectable non-interscapular site reduce that risk is unasserted by design (claim 13unconfirmed) and is precisely what an animal study would have to demonstrate. 2, not lower, because the failure mode is at least correctly identified and designed against. | A full read of PMC11383148, the feline injection-site-sarcoma literature, and the SUB complication PMC records already surfaced by title would sharpen this — free, a few hours of Tier 3 reading. Only a prospective multi-year feline case…the rest of this gap analysisseries can actually quantify the oncologic risk — Tier 3, expensive. |
| Capital intensity & time-to-revenue | 3 | Rests on claim 14unconfirmed, with claim 1unconfirmed as the enabling condition. Low-single-digit millions to first revenue is credible given no premarket submission, no user fee and no FDA clinical evidence requirement (claim 1unconfirmed) — cost is dominated by implant…the rest of this reasoningmaterial qualification, sterile packaging validation and tooling. The reason this is 3 and not 4 is calendar, not cash: claim 14unconfirmed correctly identifies that the pacing item is a prospective teaching-hospital case series with follow-up long enough to say anything about tumour incidence, and oncologic follow-up in a species where the risk window is years is not compressible with money. There is also a real tension the Generator does not resolve — nothing legally requires that study before sale, so "time to first revenue" and "time to defensible revenue" are different numbers here and only the second is scored. | Cost side: contract-manufacturer quotes for ISO 10993 biocompatibility and ISO 11607 sterile-barrier testing plus tooling — cheap, a few RFQs. Calendar side: a partner teaching-hospital's study protocol and IACUC timeline — Tier 3, no cost…the rest of this gap analysisestimate without one. |
| Competitive intensity | 2 | Rests on claims 15 and 3. Incumbents are named and real: existing feline subcutaneous fluid port products already marketed as a needleless alternative to daily injections (claim 3unconfirmed), and the SUB device manufacturer in the adjacent…the rest of this reasoningindication (claims 6, 15). claim 3unconfirmed explicitly notes the category's existence cuts against novelty as much as it supports feasibility. Combined with claim 12unconfirmed's zero regulatory barrier to a fast-follower, the space should be read as occupied and cheap to enter. 2 rather than lower because the named incumbents are small and the specific combination claimed here (low-fouling surface + metered owner-operated giving set + non-interscapular sited implant) does not obviously exist in a marketed product. | Veterinary trade sources, human-attached: distributor catalogues (Covetrus, Patterson Vet, MWI), VMX/WVC exhibitor lists, ACVIM/ACVS abstract books — free to pull, time-cost to compile. PatentsView (free once keyed) is the one database…the rest of this gap analysisthat does see this field. |
| Strategic fit & portfolio balance | *(blank — no claim, no referent)* | Unscored for two independent reasons. First, no claim in this file addresses portfolio fit — nothing to rest a score on, and Stage 2 does not invent one. Second, and more fundamental, there is no portfolio-state document anywhere in…the rest of this reasoningthis repo to score against:knowledge-base/candidates/ holds eight unrelated in-flight ideas, none of which constitutes a stated portfolio thesis, capital position, or hero-bet/cash-spoke allocation. Scoring "fit" with no referent would be a number about nothing. Worth recording for the humans that this candidate's shape is legible even unscored — vet-only, cash-pay, low regulatory burden, modest TAM — which reads as a cash-generative spoke rather than a hero bet, but whether that is wanted is not an agent's call. | A human-stated portfolio thesis and capital-allocation posture at Stage 6 shortlist review — no cost beyond that conversation; no connector or literature can supply it. |
All eight wrap criteria are met.
Source file: knowledge-base/candidates/idea-007.md
Nothing on this page is a recommendation. Shortlist review, legal and clinical sign-off and capital allocation are human-only decisions, and no agent in this repo may make or simulate one. This is a compilation of what the candidate file says.
_shared/plain-language.md